Guggenheim analyst Seamus Fernandez raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $140 from $120 and keeps a Buy rating on the shares. Last week’s preliminary Prader-Willi syndrome data for setmelanotide suggests “promising” monotherapy activity in this indication, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $157 from $141 at Goldman Sachs
- Promising Clinical Results and Market Potential Drive Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals price target raised to $141 from $114 at Canaccord
- Rhythm Pharmaceuticals price target raised to $167 from $141 at Citizens
- Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals